

KING PHARMACEUTICALS INC

Form 8-K

February 19, 2004

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 19, 2004

King Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Tennessee
(State or other jurisdiction
of incorporation)

0 24425
(Commission
File Number)

54-1684963
(IRS Employer
Identification Number)

501 Fifth Street, Bristol, Tennessee
(Address of principal executive offices)

37620
(Zip Code)

Registrant's telephone number, including area code: **423-989-8000**

Not Applicable
(Former name or former address, if changed since last report)

TABLE OF CONTENTS

SIGNATURE

Exhibit Index

EX-99.1 PRESS RELEASE 02/19/04

Table of Contents

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

(c) Exhibits.

The following exhibits are filed pursuant to Item 601 of Regulation S-K:

Exhibits:

Exhibit Number	Description of Exhibit
99.1	Press Release of King Pharmaceuticals, Inc. dated February 19, 2004.

Item 12. Results of Operation and Financial Condition

On February 19, 2004, King Pharmaceuticals, Inc., a Tennessee corporation, issued a press release which announced its fourth-quarter and year-end 2003 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this report shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 19, 2004

KING PHARMACEUTICALS, INC.

By: /s/ James R. Lattanzi

James R. Lattanzi
Chief Financial Officer

Table of Contents

Exhibit Index

Exhibit Number	Description of Exhibit
99.1	Press Release of King Pharmaceuticals, Inc. dated February 19, 2004.